Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | +4.14% | +9.70% | +10.80% |
04-25 | OncoCyte Corporation announced that it has received $15.807655 million in funding | CI |
04-16 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.80% | 35.55M | D+ | ||
+9.15% | 105B | B+ | ||
-1.08% | 104B | B+ | ||
+5.79% | 22.94B | B | ||
-11.55% | 22.34B | B+ | ||
-7.01% | 19.25B | A- | ||
-37.08% | 17.08B | A- | ||
-9.91% | 16.96B | B | ||
+7.55% | 14.16B | C+ | ||
+40.04% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- OCX Stock
- Ratings OncoCyte Corporation